<DOC>
	<DOC>NCT02975453</DOC>
	<brief_summary>Evaluation of the performance of the 2MACE index in a population of nonvalvular atrial fibrillation (NVAF) patients treated with rivaroxaban in Spain</brief_summary>
	<brief_title>Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Adult patients aged 18 years or older. Patients with diagnosis of NVAF. Patients treated with rivaroxaban from at least six months prior to the study inclusion. Patients who have been given appropriate information about the study objectives and procedures and who have given their written informed consent. Patients participating in an investigational program with interventions outside of routine clinical practice. Patients who initiate treatment with rivaroxaban after the start of the study inclusion period. Prosthetic heart valves or the presence of any severe valvulopathies. Patients with severe cognitive impairment. Patients with chronic infections (HIV infection, hepatitis C virus, hepatitis B virus) or systemic autoimmune diseases. Patients with active cancer. Patients with liver insufficiency (eg. cirrhosis).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>